Tandem Diabetes Care has patented a closed-loop insulin delivery system that adjusts insulin doses based on meal announcements. The system prevents glucose level oscillations by modifying the inner insulin loop, maintaining stable glucose levels during eating periods. GlobalData’s report on Tandem Diabetes Care gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Tandem Diabetes Care Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Tandem Diabetes Care, Wearable drug delivery devices was a key innovation area identified from patents. Tandem Diabetes Care's grant share as of February 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.

Closed loop insulin delivery system with meal announcement adjustment

Source: United States Patent and Trademark Office (USPTO). Credit: Tandem Diabetes Care Inc

A recently granted patent (Publication Number: US11911595B2) outlines a system for closed-loop diabetes therapy that includes a pump mechanism for insulin delivery, a communications device receiving glucose levels from a continuous glucose monitor, and at least one processor. The processor is configured to calculate and deliver insulin doses based on a closed-loop insulin delivery algorithm, adjusting insulin levels to maintain the user's glucose and insulin on board targets. The system also includes a pre-meal scale that modifies the algorithm in response to an indication of an upcoming meal, ensuring insulin doses are tailored to the user's needs before and after eating.

Furthermore, the patent details a method for closed-loop diabetes therapy that involves receiving glucose levels from a continuous glucose monitor, calculating insulin doses based on the closed-loop algorithm, and delivering the doses with a pump mechanism. The method includes activating a pre-meal scale in response to an indication of a meal, adjusting the insulin on board target to accommodate the upcoming food intake. This innovative approach aims to provide more personalized and effective diabetes management by dynamically adapting insulin delivery based on real-time glucose levels and anticipated meals, potentially improving overall glycemic control for individuals with diabetes.

To know more about GlobalData’s detailed insights on Tandem Diabetes Care, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.